NCT00549562View on ClinicalTrials.gov

Study of Paliperidone ER in Adolescents and Young Adults With Autism

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Autism
Interventions
DRUG

Paliperidone ER

Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.

Trial Locations (1)

46202

Riley Child & Adolescent Psychiatry Clinic- Riley Hospital, Indianapolis

All Listed Sponsors
collaborator

Ortho-McNeil Janssen Scientific Affairs, LLC

INDUSTRY

lead

Indiana University School of Medicine

OTHER

NCT00549562 - Study of Paliperidone ER in Adolescents and Young Adults With Autism | Biotech Hunter | Biotech Hunter